Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy
Ryan B Rush,1– 3 Westin Klein,1,3 Sloan W Rush,1,2 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology, Southwest Retina Specialists, Amarillo, TX...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-12-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/real-world-outcomes-in-pre-existing-neovascular-age-related-macular-de-peer-reviewed-fulltext-article-OPTH |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850103195336966144 |
|---|---|
| author | Rush RB Klein W Rush SW Reinauer RM |
| author_facet | Rush RB Klein W Rush SW Reinauer RM |
| author_sort | Rush RB |
| collection | DOAJ |
| description | Ryan B Rush,1– 3 Westin Klein,1,3 Sloan W Rush,1,2 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology, Southwest Retina Specialists, Amarillo, TX, USA; 4Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USACorrespondence: Ryan B Rush, Department of Ophthalmology, Panhandle Eye Group, 7400 Fleming Blvd, Amarillo, TX, 79106, USA, Tel +1 806 351-1870, Email ryan.rush.md@gmail.comPurpose: To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA).Methods: This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA. Study and Control Group subjects had a baseline visual acuity of ≥ 20/200, a total GA lesion area of ≥ 1 mm2 and ≤ 17.5 mm2, and follow-up of 12-months following IVA commencement.Results: A total of 64 patients were analyzed. No significant differences in baseline characteristics were found between cohorts. The Study Group had a greater decrease in visual acuity [− 0.2 (− 0.24 to − 0.16) logMAR versus − 0.04 (− 0.06 to 0.02) logMAR; p< 0.0001], a greater increase in GA lesion growth [1.36 (1.09– 1.63) mm2 versus 0.52 (0.34– 0.70) mm2; p< 0.0001], and a higher incidence of exudation (p=0.0002) compared to the Control Group during the study period.Conclusion: This study suggests that patients undergoing IVA therapy for GA with pre-existing neovascular AMD have worse visual and anatomic outcomes at 12-months compared to a matched control group without pre-existing neovascularization; such patients therefore should be carefully counseled prior to initiation of IVA for the management of GA.Keywords: geographic atrophy, avacincaptad pegol, pre-existing neovascular age-related macular degeneration, complement inhibition, Izervay |
| format | Article |
| id | doaj-art-beddda3f44ca435f8b6efc4515dfb8fc |
| institution | DOAJ |
| issn | 1177-5483 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Ophthalmology |
| spelling | doaj-art-beddda3f44ca435f8b6efc4515dfb8fc2025-08-20T02:39:35ZengDove Medical PressClinical Ophthalmology1177-54832024-12-01Volume 184011401898745Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic AtrophyRush RBKlein WRush SWReinauer RMRyan B Rush,1– 3 Westin Klein,1,3 Sloan W Rush,1,2 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of Ophthalmology, Southwest Retina Specialists, Amarillo, TX, USA; 4Department of Ophthalmology, New Vision Eye Center, Vero Beach, FL, USACorrespondence: Ryan B Rush, Department of Ophthalmology, Panhandle Eye Group, 7400 Fleming Blvd, Amarillo, TX, 79106, USA, Tel +1 806 351-1870, Email ryan.rush.md@gmail.comPurpose: To evaluate real-world outcomes in subjects with pre-existing neovascular age-related macular degeneration (AMD) undergoing intravitreal avacincaptad pegol (IVA) treatment for geographic atrophy (GA).Methods: This study was undertaken as a retrospective, case-controlled assessment of patients undergoing IVA treatment for GA from 2 community-based retina practices. Patients were separated into 1) a Study Group consisting of subjects with pre-existing neovascular AMD prior to initiation of IVA for GA, and 2) a Control Group consisting of AMD subjects without neovascularization prior to initiation of IVA for GA. Study and Control Group subjects had a baseline visual acuity of ≥ 20/200, a total GA lesion area of ≥ 1 mm2 and ≤ 17.5 mm2, and follow-up of 12-months following IVA commencement.Results: A total of 64 patients were analyzed. No significant differences in baseline characteristics were found between cohorts. The Study Group had a greater decrease in visual acuity [− 0.2 (− 0.24 to − 0.16) logMAR versus − 0.04 (− 0.06 to 0.02) logMAR; p< 0.0001], a greater increase in GA lesion growth [1.36 (1.09– 1.63) mm2 versus 0.52 (0.34– 0.70) mm2; p< 0.0001], and a higher incidence of exudation (p=0.0002) compared to the Control Group during the study period.Conclusion: This study suggests that patients undergoing IVA therapy for GA with pre-existing neovascular AMD have worse visual and anatomic outcomes at 12-months compared to a matched control group without pre-existing neovascularization; such patients therefore should be carefully counseled prior to initiation of IVA for the management of GA.Keywords: geographic atrophy, avacincaptad pegol, pre-existing neovascular age-related macular degeneration, complement inhibition, Izervayhttps://www.dovepress.com/real-world-outcomes-in-pre-existing-neovascular-age-related-macular-de-peer-reviewed-fulltext-article-OPTHgeographic atrophyavacincaptad pegolpre-existing neovascular age-related macular degenerationcomplement inhibitionizervay |
| spellingShingle | Rush RB Klein W Rush SW Reinauer RM Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy Clinical Ophthalmology geographic atrophy avacincaptad pegol pre-existing neovascular age-related macular degeneration complement inhibition izervay |
| title | Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy |
| title_full | Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy |
| title_fullStr | Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy |
| title_full_unstemmed | Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy |
| title_short | Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy |
| title_sort | real world outcomes in pre existing neovascular age related macular degeneration subjects undergoing avacincaptad therapy for geographic atrophy |
| topic | geographic atrophy avacincaptad pegol pre-existing neovascular age-related macular degeneration complement inhibition izervay |
| url | https://www.dovepress.com/real-world-outcomes-in-pre-existing-neovascular-age-related-macular-de-peer-reviewed-fulltext-article-OPTH |
| work_keys_str_mv | AT rushrb realworldoutcomesinpreexistingneovascularagerelatedmaculardegenerationsubjectsundergoingavacincaptadtherapyforgeographicatrophy AT kleinw realworldoutcomesinpreexistingneovascularagerelatedmaculardegenerationsubjectsundergoingavacincaptadtherapyforgeographicatrophy AT rushsw realworldoutcomesinpreexistingneovascularagerelatedmaculardegenerationsubjectsundergoingavacincaptadtherapyforgeographicatrophy AT reinauerrm realworldoutcomesinpreexistingneovascularagerelatedmaculardegenerationsubjectsundergoingavacincaptadtherapyforgeographicatrophy |